Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

UVA Tracking #
Principal Investigator
Paul V Viscuse
Contact Phone
Official Trial Title
A Phase 2 Study of M1774 in Refractory SPOP-mutant Prostate Cancer
Study Description

The University of Virginia Comprehensive Cancer Center seeks patients ages 18 and over with Refractory SPOP-mutant Prostate Cancer for a research study. The study will evaluate an investigational drug called M1774 to see if M1774 is effective at treating your cancer. M1174 is considered investigational because it is no yet approved by the FDA to treat this disease. The purpose of this study is to learn if the M1774 will stabilize or shrink your cancer.
The study involves receiving the investigational drug, as well as coming in for study visits which include exams, laboratory tests, and procedures such as having your blood drawn, talking to the study doctor, and answering questions about how you are doing. Participation includes a screening visit, 3 visits per cycle during treatment, and a follow-up period via phone calls to keep track of how you are doing. Treatment cycles for this study are 21 days each. If you decide to take part in this study, you may continue on treatment until your disease gets worse, the side effects become too severe, or you decide you no longer want to continue.
The investigational drug M1774, as well as exams, tests, and procedures done for research purposes only will be provided at no cost to you.
More information about this study can be found at: https://clinicaltrials.gov/study/NCT05828082


No Compensation